2024-11-12 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison and Alpha/Beta Analysis**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines. 

The stock has significantly underperformed the S&P 500 (VOO) over the provided period. While the S&P 500 has seen a cumulative return of 142.82%, Pfizer has experienced a decline of 16.64%, resulting in a **-159.46%** divergence from the benchmark. This places it at the **lowest 0.0% quantile** relative to its historical performance against the S&P 500. 

**Alpha/Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Market Cap (B) |
|------------|------|------|-------|------|---------------|
| 2015-2017  | 15.6% | 17.9% | -14.6% | 0.8 | 194.74 |
| 2016-2018  | 36.6% | 17.9% | 11.9% | 0.7 | 234.69 |
| 2017-2019  | 18.7% | 22.5% | -24.4% | 0.8 | 210.66 |
| 2018-2020  | 6.5% | 32.9% | -32.6% | 0.7 | 208.60 |
| 2019-2021  | 43.9% | 32.9% | -45.9% | 0.6 | 334.64 |
| 2020-2022  | 38.0% | 29.5% | 20.2% | 0.6 | 290.38 |
| 2021-2023  | -21.8% | 49.7% | -50.6% | 0.4 | 163.15 |
| 2022-2024  | -52.8% | 46.1% | -78.0% | 0.5 | 155.62 |

The analysis reveals that Pfizer has consistently demonstrated a **lower beta** compared to the market, indicating lower volatility. However, its **alpha** has been consistently negative for most periods, implying underperformance relative to the market.

**2. Recent Price Movements**

* **Closing Price:** $26.72 (Last Market: $26.41)
* **5-Day Moving Average:** $27.46
* **20-Day Moving Average:** $28.5
* **60-Day Moving Average:** $28.88

The stock is trading below all three moving averages, suggesting a downtrend. The recent market price of $26.41 is close to the closing price, implying a potential for minor fluctuations. 

**3. Technical Indicators**

* **RSI:** 21.3 (below 30, indicating oversold conditions)
* **PPO:** -0.64 (negative value, suggesting bearish momentum)
* **Delta_Previous_Relative_Divergence:** 0.0 (-) indicating a short-term downtrend.
* **Expected Return:** 0.0% -  This indicates that, based on current data, the stock is not expected to outperform the S&P 500 over a long-term investment horizon (2 years+).

**4. Recent Earnings and Outlook**

| Date          | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

Pfizer exceeded earnings expectations for the quarter ending October 29, 2024, reporting an EPS of 1.06 against an expected EPS of 0.614. However, the company has shown inconsistent performance in recent quarters, with both positive and negative surprises. 

**5. Financial Information**

**1) Revenue and Profitability:**

| Quarter       | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $17.70B | 70.27% |
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.49B | 31.30% |

Pfizer has shown consistent revenue growth in the last few quarters, with a notable increase in profitability. 

**2) Capital and Profitability:**

| Quarter       | Equity    | ROE |
|---|---|---|
| 2024-09-30 | $92.29B | 4.84% |
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |

The company has demonstrated a steady increase in equity, with a fluctuating ROE showing both positive and negative values.

**6. News and Recent Issues**

* **Recent Earnings News:**  (Please provide the date and source for the recent earnings news for a more detailed analysis).
* **Recent Market Outlook:**  (Please provide information from FINBOLD or other reputable sources about the market outlook for PFE).
* **Analyst Opinions and Performance Highlights:**  (Please provide specific analyst opinions and performance highlights from reliable sources for a more comprehensive analysis).

**7. Overall Analysis**

Pfizer has significantly underperformed the S&P 500 in recent years, despite a consistent revenue growth and improved profitability. The stock is currently trading below its moving averages and technical indicators suggest a downtrend. The recent earnings beat for the October 2024 quarter might be a positive sign, but further analysis of the company's future prospects is needed. The overall outlook for Pfizer remains uncertain, with a 0% expected return compared to the S&P 500. Further investigation of the company's long-term growth strategy, recent news, and analyst opinions is essential for a more informed investment decision.  

